International cardiac angiosarcoma patient registry
Official title: Cardiac Angiosarcoma International Registry
Run by Immune Oncology Research Institute · NCT06715579 · Data updated 2026-11-12
This registry collects medical histories, tumor details, treatments, and outcomes from people with cardiac angiosarcoma to see which factors and therapies lead to better results.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Immune Oncology Research Institute Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Yerevan) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | May 2035 |
| Study ends | May 2035 |
| Registry record updated | February 18, 2026 |
| Trial ID | NCT06715579 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with histologically confirmed primary cardiac angiosarcoma (including hemangiosarcoma and epithelioid variants) diagnosed between January 2015 and January 2035 who can provide available clinical data and, for prospective entries, informed consent.
✕Probably not a fit
Patients without a confirmed cardiac angiosarcoma diagnosis, those lacking sufficient clinical data, or those unwilling to consent are unlikely to benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This international registry will gather standardized clinical data from patients with histologically confirmed primary cardiac angiosarcoma diagnosed between 2015 and 2035. Participating centers will submit demographics, tumor characteristics, treatment regimens (surgery, chemotherapy, immunotherapy, radiation), and follow-up outcomes into a centralized database. Investigators will analyze pooled data to identify genetic, environmental, and treatment-related factors linked to survival and complications. The assembled dataset will be used to develop evidence-based recommendations and to support future clinical trials for this rare, aggressive heart cancer.
Why it matters
Potential benefit: If successful, the registry could identify treatments and risk factors that improve diagnosis, management, and survival for people with cardiac angiosarcoma.
How similar studies have gone: Registries and multicenter databases for rare sarcomas have improved understanding of disease patterns and treatment outcomes, but cardiac angiosarcoma-specific data remain limited and this effort is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma. * Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035. * Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations. * Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes. * Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry. * Clinical Data Availability: Relevant clinical data, including demographics, tumor characteristics (size, location), treatment regimens, and outcomes, must be available for analysis. * Follow-Up Willingness: Participants should be willing to undergo follow-up assessments as part of the registry's data collection efforts. Exclusion Criteria: * Patients who decline to provide informed consent. * Cases where cardiac involvement is secondary to another primary malignancy
Where it's running
-
Yeolyan Hematology and Oncology Center
Yerevan, Armenia Recruiting
Study contacts
- Principal investigator: Shushan Hovsepyan, MD — Immune Oncology Research Institute, Yerevan, Armenia
- Study coordinator: Aharon Tsaturyan, MD
- Email: aharon3tsaturyan@gmail.com
- Phone: +374 99190152
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating balstilimab for treating relapsed lymphoma
This study is testing a new immunotherapy drug called balstilimab to see if it can help people with relapsed Hodgkin lymphoma or primary mediastinal B-cell lymphoma feel better.
-
International registry for rare embryonal tumors of the central nervous system
This study is creating a database to help doctors learn more about rare brain tumors in kids and young adults, so they can improve diagnosis and treatment, especially in places where information is limited.
-
International registry for Blastic Plasmacytoid Dendritic Cell Neoplasm
This study is creating a global database for people with Blastic Plasmacytoid Dendritic Cell Neoplasm to gather information on their experiences and treatments to help improve care for this rare cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.